FDA Proposes Priorities For Cosmetic Ingredient Review: Mica, Probiotics, CBD

Nakissa Sadrieh, director of cosmetics at FDA and the agency’s CIR liaison, floated the three potential review priorities at the CIR Expert Panel’s April 8-9 meeting in Washington. It’s the most for-cause targets proposed by the agency in recent memory, and CIR leadership noted that they pose considerable challenges.

FDA words adn building icon

Like many industry stakeholders, FDA clearly has cannabidiol (CBD) on its brain in the wake of the US farm bill’s passage late last year, which cleared barriers to wider marketing of industrial hemp-based consumer products.

Under the Agriculture Improvement Act signed into law by President Donald Trump in December 2018, hemp is defined as the...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Ingredients & Safety

More from HBW Insight